From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2024 call → NOWe need to determine if management describes a recent transition into an approved/specified/qualified status within buyers' systems, such that future business can arrive without discrete selling, and that this is new with most volume ahead. Key points from transcript: - Saleel mentions "we received our first follow-on order for the first half of fiscal year 2025 as this customer is transitioning from design and initial production to a run rate business." This indicates a transition from design/production to run rate, but is that a "gateway" status? It's about a specific customer order, not a broad approved supplier list. It's a follow-on order, but still each order is placed. Not a systemic access. - He also mentions "We are replicating this design win with multiple generator makers" - that's about design wins, not a systemic listing. - For automotive, they have a design with Togg, but that's a customer win. - For enterprise, they talk about out-of-band solutions, but no mention of being on approved lists. The question asks: does management describe that the company has recently crossed from being a candidate to being an approved/specified/listed/qualified/etc. inside buyers' systems, so that future business can arrive without a discrete selling event? And that this is new with most volume ahead. The transcript does not mention any such status. It talks about design wins, follow-on orders, and ramping production. That's typical selling relationships. No mention of being added to a procurement schedule, approved vendor list, or any systemic pathway. The closest is "transitioning from design and initial production to a run rate business" but that's about a specific customer's order flow, not a systemic access. Also, the follow-on order is for first half of fiscal 2025, but that's still an order. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.